Other languages Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
4.68 ^USD	-0.43%		-2.45%	+67.74%

05-01	Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	CI
04-12	Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	05-01
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	04-12
Top Premarket Gainers	04-11
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	04-11
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	03-28
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug	03-25
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	03-25
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	02-06
Lipocine Enters Licensing Deal With Verity Pharmaceuticals for TLANDO in US, Canada	01-18
Lipocine and Verity Pharma Enter into License Agreement for Tlando® Franchise in the U.S. and Canada	01-18
Lipocine Inc. Announces Results of its Phase 2 Study Evaluating LPCN 1148	11-13
Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Lipocine Inc. Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression	26/10/23
Lipocine Inc. Enters into License Agreement with Antares Pharma, Inc	06/10/23
Lipocine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Lipocine Inc. Announces Positive Topline Results from A Phase 2 Clinical Study of LPCN 1148	27/07/23
Lipocine Says Pilot Study of LPCN 1154 for Postpartum Depression Shows 'Positive' Topline Results	16/05/23
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Lipocine Inc. Doses First Participent in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154	03/04/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lipocine Inc.

Equities

LPCN

US53630X2036

Other languages

Filters